TTOO Competitors

TTOO Stock  USD 2.99  0.05  1.70%   
T2 Biosystms competes with Genetic Technologies, Intelligent Bio, BioAffinity Technologies, Thermo Fisher, and Illumina; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing T2 Biosystms competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of T2 Biosystms to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out T2 Biosystms Correlation with its peers.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of T2 Biosystms competition on your existing holdings.
  
At this time, T2 Biosystms' Return On Capital Employed is very stable compared to the past year. As of the 19th of April 2024, Return On Equity is likely to grow to 1.88, while Return On Tangible Assets are likely to drop (1.51). At this time, T2 Biosystms' Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Current Assets Total is likely to grow to about 11.6 M, while Non Currrent Assets Other are likely to drop 3,799.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of T2 Biosystms' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.142.889.77
Details
Intrinsic
Valuation
LowRealHigh
0.224.3811.27
Details
Naive
Forecast
LowNextHigh
0.062.899.78
Details
1 Analysts
Consensus
LowTargetHigh
7.908.689.63
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as T2 Biosystms. Your research has to be compared to or analyzed against T2 Biosystms' peers to derive any actionable benefits. When done correctly, T2 Biosystms' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in T2 Biosystms.

T2 Biosystms Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between T2 Biosystms and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of TTOO and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of T2 Biosystms does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
HTGMBIOC
SQLBIOC
SQLHTGM
BIAFGENE
TMOIDXG
TMOGENE
  
High negative correlations   
ILMNGENE
GENEBIOC
TMOSQL
ILMNBIAF
SQLGENE
TMOBIOC

Risk-Adjusted Indicators

There is a big difference between TTOO Stock performing well and T2 Biosystms Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze T2 Biosystms' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare T2 Biosystms and related stocks such as Biocept, Genetic Technologies, and HTG Molecular Diagnostics Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
GENE(2.4 M)(5.3 M)(9.3 M)(10.1 M)(8.8 M)(8.5 M)(8.4 M)(5.5 M)(6.8 M)(6.3 M)(7.2 M)(7.1 M)(11.8 M)(10.6 M)(11.1 M)
INBS(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(7.3 M)(3.7 M)(11 M)(8.3 M)(8.3 M)(7.5 M)(7.8 M)
BIAF(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(7.3 M)(6.3 M)(8.2 M)(7.9 M)(8.3 M)
TMO9.6 M1.3 B1.2 B1.3 B1.9 BBB2.2 B2.9 B3.7 B6.4 B7.7 BBB6.3 B
ILMN(5.5 M)86.6 M151.3 M125.3 M353.4 M461.6 M462.6 M726 M826 MB656 M762 M(4.4 B)(1.2 B)(1.1 B)
DHR5.6 M2.2 B2.4 B2.7 B2.6 B3.4 B2.6 B2.5 B2.7 BB3.6 B6.4 B7.2 B4.7 BB
WATM433 M461.4 M450 M431.6 M469.1 M521.5 M20.3 M593.8 M592.2 M521.6 M692.8 M707.8 M642.2 M350.8 M
IDXX3.2 M161.8 M178.3 M187.8 M181.9 M192.1 M222 M263.1 M377 M427.7 M581.8 M744.8 M679.1 M845 M887.3 M
ISPC(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(4.7 M)(6.8 M)(10 M)(9 M)(11.1 M)(11.7 M)

T2 Biosystms and related stocks such as Biocept, Genetic Technologies, and HTG Molecular Diagnostics Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in T2 Biosystms financial statement analysis. It represents the amount of money remaining after all of T2 Biosystms operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

T2 Biosystms Competitive Analysis

The better you understand T2 Biosystms competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, T2 Biosystms' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across T2 Biosystms' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TTOO BIOC GENE HTGM INBS IDXG BIAF SQL TMO ILMN
 1.70 
 2.99 
TTOO
 125.16 
 0.07 
Biocept
 22.78 
 2.44 
Genetic
 2.94 
 0.35 
HTG
 4.48 
 2.80 
Intelligent
 1.87 
 1.09 
Interpace
 4.12 
 2.79 
BioAffinity
 19.84 
 4.00 
SeqLL
 1.05 
 541.52 
Thermo
 1.35 
 116.69 
Illumina
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

T2 Biosystms Competition Performance Charts

Five steps to successful analysis of T2 Biosystms Competition

T2 Biosystms' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by T2 Biosystms in relation to its competition. T2 Biosystms' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of T2 Biosystms in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact T2 Biosystms' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to T2 Biosystms, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your T2 Biosystms position

In addition to having T2 Biosystms in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Software Thematic Idea Now

Software
Software Theme
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
View All  Next Launch
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:
Check out T2 Biosystms Correlation with its peers.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for TTOO Stock analysis

When running T2 Biosystms' price analysis, check to measure T2 Biosystms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy T2 Biosystms is operating at the current time. Most of T2 Biosystms' value examination focuses on studying past and present price action to predict the probability of T2 Biosystms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move T2 Biosystms' price. Additionally, you may evaluate how the addition of T2 Biosystms to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is T2 Biosystms' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(19.19)
Revenue Per Share
2.756
Quarterly Revenue Growth
(0.69)
Return On Assets
(0.85)
Return On Equity
(6.22)
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.